1. The DAVIO trial: a phase 1, open-label, dose-escalation study of a single injection of EYP-1901 (vorolanib in Durasert® platform) demonstrating reduced treatment burden in wet age-related macular degeneration;Abbey;Invest Ophthalmol Vis Sci,2023
2. Intravitreal Therapy for Uveitic Macular Edema—Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results;Acharya;Ophthalmology,2023
3. Nanoparticle-based Technologies for Retinal Gene Therapy;Adijanto;Eur J Pharm Biopharm J Arb Pharm Verfahr EV,2015
4. Adverum Biotechnologies, Inc. A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA] [Internet]. clinicaltrials.gov; 2023 May [cited 2023 Jan 1]. Report No.: NCT05536973. Available from: 〈https://clinicaltrials.gov/study/NCT05536973〉.
5. Liposome-bound cyclosporine: retinal toxicity after intravitreal injection;Alghadyan;Int Ophthalmol,1988